Q&A: Remicade treatment weakens COVID-19 antibody response in IBD

Q&A: Remicade treatment weakens COVID-19 antibody response in IBD

Patients who received Remicade for inflammatory bowel disease had weakened anti-COVID-19 antibody responses following a single vaccination dose, according to research published in Gut.In a prospective, observational cohort study, researchers compared antibody responses and seroconversion rates in Remicade-treated (infliximab, Janssen) patients (n = 856) vs. Entyvio-treated (vedolizumab, Takeda) patients (n = 428) 3-weeks to 10-weeks after receiving a single dose of a SARS-CoV-2 vaccine.According to study results, patients treated with infliximab had lower anti-SARS-CoV-2 antibodyRead More

Share on facebook
Share on twitter
Share on linkedin